You are viewing a preview of...
Type II Transmembrane Serine Protease Inhibitors as Host-based Broad Range Antivirals
Treatment would protect individuals during development of vaccines or therapeutic treatments for respiratory viruses and their variants
Type II transmembrane serine proteases (TTSPs) have been identified as potential therapeutic targets for the treatment of respiratory infections by coronaviruses, MERS and influenza. These enzymes are involved in a key component of viral infection (viral spike protein processing) which enable the virus to enter the host cells.
Researchers have developed ketobenzothiazole containing peptidomimetic protease inhibitors in a previous influenza program. So far, preclinical data demonstrate potent antiviral activity against SARS-CoV-2 infection in vitro as well as in vivo in a prophylactic paradigm.
This host-based, broad range respiratory antiviral class of compound is well positioned as a key preparedness step for potential future pandemics requiring immediate intervention when vaccines are not readily available.
Log in or create a free account to continue reading